{
    "paper_id": "b2f59ed63b03f298f809f4aaefc80dc3e0415685",
    "metadata": {
        "title": "Review Antiviral combinations for severe infl uenza",
        "authors": [
            {
                "first": "Jake",
                "middle": [
                    "J"
                ],
                "last": "Dunning",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Kenneth",
                "middle": [],
                "last": "Baillie",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Bin",
                "middle": [],
                "last": "Cao",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Frederick",
                "middle": [
                    "G"
                ],
                "last": "Hayden",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "Observational data suggest that the treatment of infl uenza infection with neuraminidase inhibitors decreases progression to more severe illness, especially when treatment is started soon after symptom onset. However, even early treatment might fail to prevent complications in some patients, particularly those infected with novel viruses such as the 2009 pandemic infl uenza A H1N1, avian infl uenza A H5N1 virus subtype, or the avian infl uenza A H7N9 virus subtype. Furthermore, treatment with one antiviral drug might promote the development of antiviral resistance, especially in immunocompromised hosts and critically ill patients. An obvious strategy to optimise antiviral therapy is to combine drugs with diff erent modes of action. Because host immune responses to infection might also contribute to illness pathogenesis, improved outcomes might be gained from the combination of antiviral therapy with drugs that modulate the immune response in an infected individual. We review available data from preclinical and clinical studies of combination antiviral therapy and of combined antiviral-immunomodulator therapy for infl uenza. Earlystage data draw attention to several promising antiviral combinations with therapeutic potential in severe infections, but there remains a need to substantiate clinical benefi t. Combination therapies with favourable experimental data need to be tested in carefully designed aclinical trials to assess their effi cacy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "Infl uenza virus infection causes substantial morbidity and mortality, despite the availability of antiviral drugs and vaccines. WHO estimates that annual epidemics cause 3 million to 5 million cases of severe illness and 250 000-500 000 deaths worldwide. 1 After the 2009 pandemic, outbreaks of that strain have continued to cause serious illness and increased mortality, particularly in young adults and children. 2,3 The increase of zoonotic infections with avian infl uenza viruses is also of concern.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "A second wave of avian infl uenza H7N9 occurred in China in late 2013 to early 2014, with high rates of severe illness and death in patients with confi rmed infection, and the virus continues to circulate in poultry. 4 For the fi rst time, 5 severe avian infl uenza A H10N8 infection in human beings has been described, and cases of avian infl uenza A H5N1 continue to be reported, including the fi rst case of imported infection in North America. 6 Various observational studies in seasonal, pandemic or avian infl uenza H5N1 infections show that timely oseltamivir monotherapy can reduce the risk of severe infl uenza outcomes such as pneumonia and admission to hospital and lower mortality in hospital inpatients, including risk groups such as pregnant women and immuno compromised hosts. 7-15 However, monotherapy has not prevented death in many patients with severe pandemic H1N1, 16 H5N1, 15 or H7N9 illness. 17 Although various factors might account for these deaths, oseltamivir treatment is associated with incomplete antiviral responses in severely ill patients, in whom viral detection can persist in the upper and, more often, the lower respiratory tract for days to sometimes weeks during otreatment. [17] [18] [19] [20] Furthermore, emergence of resistance during monotherapy has been a drawback in severe infl uenza, particularly in immuno compromised hosts 21 and in avian H5N1 22 and H7N9 infections. 17, 23 Variants with highly reduced inhibition by oseltamivir in vitro have sometimes emerged within several days of initiation of therapy in severe infl uenza caused by by pandemic H1N1 21 or avian viruses. 17, 23 Modelling studies based on human viral kinetics show that all possible single nucleotide mutations and a sizeable proportion of double ones are generated during an uncomplicated infl uenza infection. 24 Whereas most of these mutations sustain a fi tness cost, some variants show reduced inhibition and be selected during drug therapy. Therapeutic use of infl uenza antiviral combinations could increase antiviral potency and reduce resistance emergence; both of these eff ects could increase clinical eff ectiveness, especially in seriously ill or immunocompromised hosts. Additionally, combinations might allow dose-sparing in the event of drug shortages and possibly reduce risks of adverse drug eff ects.",
            "cite_spans": [
                {
                    "start": 217,
                    "end": 218,
                    "text": "4",
                    "ref_id": null
                },
                {
                    "start": 448,
                    "end": 449,
                    "text": "6",
                    "ref_id": null
                },
                {
                    "start": 886,
                    "end": 888,
                    "text": "16",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 895,
                    "end": 897,
                    "text": "15",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 915,
                    "end": 917,
                    "text": "17",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1214,
                    "end": 1218,
                    "text": "[17]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1219,
                    "end": 1223,
                    "text": "[18]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 1224,
                    "end": 1228,
                    "text": "[19]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 1229,
                    "end": 1233,
                    "text": "[20]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 1373,
                    "end": 1375,
                    "text": "21",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 1394,
                    "end": 1396,
                    "text": "22",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 1418,
                    "end": 1421,
                    "text": "17,",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1422,
                    "end": 1424,
                    "text": "23",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 1626,
                    "end": 1629,
                    "text": "17,",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1630,
                    "end": 1632,
                    "text": "23",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 1833,
                    "end": 1835,
                    "text": "24",
                    "ref_id": "BIBREF10"
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "The broad range of responses to infection, as seen by the high rates of clinically inapparent infections reported by seroepidemiological studies, 25 shows that the severity of infl uenza is at least, in part, determined by host factors. Death in many cases is a result of irreversible lung injury related to both host infl ammatory responses and direct cellular eff ects of viral infection (cytopathology and apoptosis). Hence, modulation of the host proinfl ammatory response might be a tractable complementary therapeutic strategy and off ers an advantage compared with antivirals in avoiding emergence of drug-resistant variants. Furthermore, some host-cell pathways are essential for viral replication, so that some host-directed inhibitors have the potential to diminish both viral replication and harmful infl ammatory responses. 26 The well established therapeutic approach of antiviral combinations has received only limited clinical testing in infl uenza infections so far, and very little information is available from studies in hospitalised or severely ill patients with infl uenza. Consequently, no combinations of proven value for treatment of severe human infl uenza are now available. In this Review, we summarise published information regarding infl uenza antiviral combinations Review and comment on antiviral and immunomodulator combin ations that have received preclinical and, in some instances, clinical investigation. The details of representative studies of antiviral combinations and of antiviral and immunomodulator combinations are listed in the appendix. Several of these regimens would be candidates for controlled studies in hospital inpatients with serious infl uenza infections, including patients infected with avian infl uenza A H7N9 virus, or in patients who are immunocompromised with an increase in the risk of severe disease and resistance emergence.",
            "cite_spans": [
                {
                    "start": 146,
                    "end": 148,
                    "text": "25",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 836,
                    "end": 838,
                    "text": "26",
                    "ref_id": "BIBREF12"
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "As previously reviewed, 27, 28 in-vitro studies showing enhanced antiviral activity against infl uenza A virus with dual drug regimens of amantadine and interferon date to 1968 29 and ofrimantadine and ribavirin date to 1977. 30 Combinations of amantadine and ribavirin were reported to increase survival in murine models of infl uenza A virus infection, 30 although not of infl uenza B. 31 Reduction in adamantane resistance emergence in vitro by combination of rimantadine and ribavirin was reported in 1980, 32 a principle subsequently supported with amantadine and oseltamivir for many infl uenza A subtypes, including avian H5N1. 33 The fi rst triple infl uenza drug regimen (interferon alfa, rimantadine, and ribavirin) showing enhanced in-vitro activity against infl uenza A was described in 1984; 34 the investigators also noted enhanced activity with combinations of ribavirin and interferon alfa for an infl uenza B virus. Once neuraminidase inhibitors became available, preclinical studies showed additive or synergistic in-vitro activity and increased survival in murine models with combinations of an adamantane with a neuraminidase inhibitor. [35] [36] [37] [38] [39] [40] The fi rst randomised controlled trial of combination therapy in hospital inpatients, done by the Collaborative Antiviral Study Group in the late 1990s, showed that a regimen of oral rimantadine and nebulised zanamivir seemed to exert a slightly greater antiviral eff ect and prevent emergence of adamantane resistance compared with one of rimantadine and nebulised saline. 41 A subsequent randomised controlled trial in outpatients reported evidence for possible antagonism with a combination of oral oseltamivir and inhaled zanamivir, 42 an observation that emphasised the importance of detailed preclinical studies before embarking on clinical trials. Subsequent studies have led to several randomised controlled trials testing the safety and effi cacy of various combinations of infl uenza antivirals (table 1) .",
            "cite_spans": [
                {
                    "start": 24,
                    "end": 27,
                    "text": "27,",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 28,
                    "end": 30,
                    "text": "28",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 177,
                    "end": 179,
                    "text": "29",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 226,
                    "end": 228,
                    "text": "30",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 355,
                    "end": 357,
                    "text": "30",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 388,
                    "end": 390,
                    "text": "31",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 635,
                    "end": 637,
                    "text": "33",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1157,
                    "end": 1161,
                    "text": "[35]",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 1162,
                    "end": 1166,
                    "text": "[36]",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 1167,
                    "end": 1171,
                    "text": "[37]",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 1172,
                    "end": 1176,
                    "text": "[38]",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 1177,
                    "end": 1181,
                    "text": "[39]",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 1182,
                    "end": 1186,
                    "text": "[40]",
                    "ref_id": "BIBREF28"
                },
                {
                    "start": 1561,
                    "end": 1563,
                    "text": "41",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 1724,
                    "end": 1726,
                    "text": "42",
                    "ref_id": "BIBREF30"
                }
            ],
            "ref_spans": [
                {
                    "start": 1992,
                    "end": 2001,
                    "text": "(table 1)",
                    "ref_id": "TABREF1"
                }
            ],
            "section": "Historical perspectives"
        },
        {
            "text": "At present, circulating infl uenza viruses including avian infl uenzas H7N9 and H5N1 are susceptible to neuraminidase inhibitors, and ovesrvational clinical data show reduced mortality with timely oseltamivir therapy in H5N1 disease. 15 Most preclinical studies show at least additive and often synergistic interactions between neuraminidase inhibitors and antiviral drugs with diff erent mechanisms of action. Consequently, oseltamivir or, if available, intravenous zanamivir or peramivir would be a logical choice for use as a foundation drug in testing of an antiviral combination.",
            "cite_spans": [
                {
                    "start": 234,
                    "end": 236,
                    "text": "15",
                    "ref_id": "BIBREF1"
                }
            ],
            "ref_spans": [],
            "section": "Neuraminidase inhibitors"
        },
        {
            "text": "Several issues emerge when the possibility of dual neuraminidase inhibitor therapy is considered. The use of dual neuraminidase inhibitors combinations might off er the possibility of reduced resistance emergence because of diff ering antiviral resistance profi les among these drugs. 47 However, data have not substantiated this potential advantage. Combinations of oseltamivir and zanamivir or peramivir show concentration-dependent additive to antagonistic antiviral eff ects for H1N1 viruses in vitro, 48 whereas another study reported that combinations of oseltamivir and peramivir show mainly additive activities in vitro and in mice. 49 Review the similarities in chemical structure of oseltamivir and peramivir. In either instance, no greater antiviral eff ects than the more potent drug of the two would be expected. Infl uenza A neuraminidases form two groups on phylogenetic analysis: group 1 (N1, N4, N5, and N8) and group 2 (N2, N3, N6, N7, and N9). Each group has distinctive structural features, including a protein loop, the 150-loop, that has an open active-site conformation in group 1 neuraminidases and a closed active-site conformation in group 2 neuraminidases. 50 Although both oseltamivir and zanamivir inhibit both groups to a similar degree, some oseltamivir-resistant viruses show neuraminidase group specifi city that is mediated by specifi c aminoacid changes. 47, 51 N9 aminoacid substitutions selected in vitro by oseltamivir include several also seen in H3N2 viruses in patients given oseltamivir (eg, Arg292Lys and Glu119Val in N2 numbering). 52, 53 Although the catalytic site Arg292Lys substitution causes a marked fi tness loss in H3N2, it also confers highly reduced inhibition by oseltamivir (>1000-fold reduction) in enzyme inhibition assays and reduced inhibition by zanamivir and to greater extent by peramivir. 52 This substitution (Arg294Lys in N9 numbering) also causes highly reduced inhibition by oseltamivir and peramivir and reduced inhibition by zanamivir in avian infl uenza H7N9 in vitro, 54 and absence of inhibition in mice given neuraminidase inhibitors. 55 Of note, emergence of the Arg292Lys substitution has been reported as early as 2 days after initiation of oseltamivir in patients infected with iH7N9 and has been associated with poor clinical outcomes. 17,56 H7N9 variants with Arg292Lys replicate at least as well in Madin-Darby canine kidney-SIAT1 cells and primary human respiratory cells as susceptible virus 54 and show similar virulence in mice and transmissibility in guineapigs. 57 Such fi ndings show that the fi tness eff ects of Arg292Lys in the N9 background are much less than those reported for H3N2 viruses and that this substitution might render all available neuraminidase inhibitors clinically ineff ective.",
            "cite_spans": [
                {
                    "start": 285,
                    "end": 287,
                    "text": "47",
                    "ref_id": "BIBREF35"
                },
                {
                    "start": 506,
                    "end": 508,
                    "text": "48",
                    "ref_id": "BIBREF36"
                },
                {
                    "start": 641,
                    "end": 643,
                    "text": "49",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 1184,
                    "end": 1186,
                    "text": "50",
                    "ref_id": "BIBREF38"
                },
                {
                    "start": 1390,
                    "end": 1393,
                    "text": "47,",
                    "ref_id": "BIBREF35"
                },
                {
                    "start": 1394,
                    "end": 1396,
                    "text": "51",
                    "ref_id": "BIBREF39"
                },
                {
                    "start": 1576,
                    "end": 1579,
                    "text": "52,",
                    "ref_id": "BIBREF40"
                },
                {
                    "start": 1580,
                    "end": 1582,
                    "text": "53",
                    "ref_id": "BIBREF41"
                },
                {
                    "start": 1853,
                    "end": 1855,
                    "text": "52",
                    "ref_id": "BIBREF40"
                },
                {
                    "start": 2040,
                    "end": 2042,
                    "text": "54",
                    "ref_id": "BIBREF42"
                },
                {
                    "start": 2109,
                    "end": 2111,
                    "text": "55",
                    "ref_id": "BIBREF43"
                },
                {
                    "start": 2475,
                    "end": 2477,
                    "text": "54",
                    "ref_id": "BIBREF42"
                },
                {
                    "start": 2549,
                    "end": 2551,
                    "text": "57",
                    "ref_id": "BIBREF45"
                }
            ],
            "ref_spans": [],
            "section": "Neuraminidase inhibitors"
        },
        {
            "text": "In healthy volunteers, the combined administration of intravenous zanamivir and oral oseltamivir 44 or of intra venous peramivir and oral oseltamivir 43 shows no important pharmacokinetic interactions. One randomised double-blind, placebo-controlled trial identifi ed slower virological and clinical responses in patients given combined therapy with oseltamivir and inhaled zanamivir compared with oseltamivir alone in treatment of uncomplicated, mostly H3N2 infl uenza in adults, 42 although the combination might have been more eff ective in reducing secondary transmission. 58 A small randomised controlled trial in outpatients infected with 2009 pandemic H1N1 virus did not show obvious diff erences in antiviral eff ects with the combination compared with oseltamivir alone. 59 However, an observational study in oseltamivir-pretreated, severely ill patients with pandemic H1N1 virus showed that late switch to intravenous zanamivir was associated with sustained viral-load reductions in three of three patients given zanamivir monotherapy but in only three of ten given combined therapy with oseltamivir. 60 Another open-label trial in critically ill patients with pandemic H1N1 virus reported persistent viral detection, with 75% still RNA positive for infl uenza at 7 days after the start of treatment, despite administration of a combination of higher dose oral oseltamivir and inhaled zanamivir. 61 Consequently, these results raise concerns about adverse interactions for combinations of zanamivir and oseltamivir; further preclinical assessment, including enzyme inhibition studies, is warranted before use in clinical practice.",
            "cite_spans": [
                {
                    "start": 150,
                    "end": 152,
                    "text": "43",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 481,
                    "end": 483,
                    "text": "42",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 577,
                    "end": 579,
                    "text": "58",
                    "ref_id": "BIBREF46"
                },
                {
                    "start": 780,
                    "end": 782,
                    "text": "59",
                    "ref_id": "BIBREF47"
                },
                {
                    "start": 1111,
                    "end": 1113,
                    "text": "60",
                    "ref_id": "BIBREF48"
                },
                {
                    "start": 1406,
                    "end": 1408,
                    "text": "61",
                    "ref_id": "BIBREF49"
                }
            ],
            "ref_spans": [],
            "section": "Neuraminidase inhibitors"
        },
        {
            "text": "Most circulating or threatening infl uenza viruses at present are adamantane-resistant, including avian A H7N9, pandemic H1N1, avian H10N8, and seasonal H3N2 viruses. However, adamantane resistance is variable in avian H5N1 viruses, and many isolates have been susceptible. 62 In preclinical studies with adamantanesusceptible infl uenza A virus, the combined use of an adamantane with a neuraminidase inhibitor or ribavirin generally shows additive or synergistic interactions in vitro 30, 37, 63, 64 and increased survival in murine models of infl uenza, including avian H5N1 virus. 30, 33, 35, 65 However, if an infl uenza virus is adamantane-resistant, no additional survival benefi t or antiviral eff ect has been shown when adamantane has also been given compared with oseltamivir or ribavirin monotherapy, although one study reported increased survival with dual combinations of amantadine and oseltamivir or ribavirin for an adamantane-resistant 2009 pandemic H1N1 virus in mice. 66 Human studies of combinations of oral oseltamivir and amantadine 67 and of oral rimantadine and intravenous peramivir 43 have shown no important pharmacokinetic interactions. One placebo-controlled but underpowered trial of nebulised zanamivir in patients with infl uenza A who had been admitted to hospital, all of whom were given rimantadine, showed trends towards faster cough resolution and lesser risk of adamantane resistance emergence. 41 Consequently, a dual regimen of an adamantane and neuraminidase inhibitor would be a reasonable initial treatment regimen for serious infl uenza when the infecting strain is probably susceptible to both drug classes.",
            "cite_spans": [
                {
                    "start": 274,
                    "end": 276,
                    "text": "62",
                    "ref_id": "BIBREF50"
                },
                {
                    "start": 487,
                    "end": 490,
                    "text": "30,",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 491,
                    "end": 494,
                    "text": "37,",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 495,
                    "end": 498,
                    "text": "63,",
                    "ref_id": "BIBREF51"
                },
                {
                    "start": 499,
                    "end": 501,
                    "text": "64",
                    "ref_id": "BIBREF52"
                },
                {
                    "start": 585,
                    "end": 588,
                    "text": "30,",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 589,
                    "end": 592,
                    "text": "33,",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 593,
                    "end": 596,
                    "text": "35,",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 597,
                    "end": 599,
                    "text": "65",
                    "ref_id": "BIBREF53"
                },
                {
                    "start": 988,
                    "end": 990,
                    "text": "66",
                    "ref_id": "BIBREF54"
                },
                {
                    "start": 1056,
                    "end": 1058,
                    "text": "67",
                    "ref_id": "BIBREF55"
                },
                {
                    "start": 1109,
                    "end": 1111,
                    "text": "43",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 1434,
                    "end": 1436,
                    "text": "41",
                    "ref_id": "BIBREF29"
                }
            ],
            "ref_spans": [],
            "section": "Adamantanes"
        },
        {
            "text": "Combinations of ribavirin with neuraminidase inhibitors have shown variable interactions. Peramivir and ribavirin showed synergistic activity for an H1N1 virus in vitro and enhanced survival eff ects when given orally in combination compared with suboptimum doses of either agent. 68 Several oseltamivir and ribavirin dose combinations increased survival, reduced lung consolidation, and Review reduced lung viral titres in infl uenza B compared with suboptimum doses of single agents, whereas one dosing regimen of oseltamivir and ribavirin showed no greater eff ects than ribavirin alone for mice injected with A/New Caledonia/20/99 H1N1. 69 Ribavirin and oseltamivir have shown mainly additive interactions in preclinical assays with H5N1. 40, 65, 70, 71 In mice infected with avian H5N1 virus, oseltamivir and ribavirin also showed exceptions of marginal synergy or slight antagonism at some dose combinations. 6 In uncomplicated seasonal infl uenza, randomised controlled trials show that ribavirin monotherapy is ineff ective at doses of 1 g per day 72 and only marginally benefi ts clinical manifestations at higher doses of 8\u00b74 g given over 2 days. 73 Aerosolised and intravenous ribavirin preparations have been used with possible benefi t in severely ill patients with infl uenza, 74,75 and a combination of oral ribavirin and amantadine was used in the treatment of infl uenza pneumonia in a pregnant patient who survived. 76 However, an assessment by US Food and Drug Administration experts concluded that the data from compassionate use reports of intravenous ribavirin in infl uenza were inconclusive in terms of clinical benefi ts and also pointed out the potential safety issues associated with ribavirin, such as haemolytic anaemia and teratogeniocity. 77",
            "cite_spans": [
                {
                    "start": 281,
                    "end": 283,
                    "text": "68",
                    "ref_id": "BIBREF56"
                },
                {
                    "start": 641,
                    "end": 643,
                    "text": "69",
                    "ref_id": "BIBREF57"
                },
                {
                    "start": 743,
                    "end": 746,
                    "text": "40,",
                    "ref_id": "BIBREF28"
                },
                {
                    "start": 747,
                    "end": 750,
                    "text": "65,",
                    "ref_id": "BIBREF53"
                },
                {
                    "start": 751,
                    "end": 754,
                    "text": "70,",
                    "ref_id": "BIBREF58"
                },
                {
                    "start": 755,
                    "end": 757,
                    "text": "71",
                    "ref_id": "BIBREF59"
                },
                {
                    "start": 915,
                    "end": 916,
                    "text": "6",
                    "ref_id": null
                },
                {
                    "start": 1056,
                    "end": 1058,
                    "text": "72",
                    "ref_id": "BIBREF60"
                },
                {
                    "start": 1157,
                    "end": 1159,
                    "text": "73",
                    "ref_id": "BIBREF61"
                },
                {
                    "start": 1434,
                    "end": 1436,
                    "text": "76",
                    "ref_id": "BIBREF64"
                }
            ],
            "ref_spans": [],
            "section": "Ribavirin"
        },
        {
            "text": "A TCAD regimen (Adamas, Emeryville, CA, USA) of three available agents (amantadine, ribavirin, and oseltamivir) shows synergistic activity in vitro against not only infl uenza A viruses that are susceptible, 78 but also those resistant to the adamantanes or oseltamivir at baseline, including adamantane-resistant 2009 pandemic H1N1 virus. 48 TCAD was more inhibitory than any of the dual combinations and was also more eff ective at preventing resistance emergence during in-vitro passage. 79 Murine model studies reported greater survival than with dual combinations for an adamantanesusceptible H5N1 virus and also for an adamantaneresistant pandemic H1N1 virus. 66 However, virological data were not provided to establish whether the improved survival was associated with greater antiviral eff ects or possibly reduced resistance emergence in vivo.",
            "cite_spans": [
                {
                    "start": 208,
                    "end": 210,
                    "text": "78",
                    "ref_id": "BIBREF66"
                },
                {
                    "start": 340,
                    "end": 342,
                    "text": "48",
                    "ref_id": "BIBREF36"
                },
                {
                    "start": 491,
                    "end": 493,
                    "text": "79",
                    "ref_id": "BIBREF67"
                },
                {
                    "start": 666,
                    "end": 668,
                    "text": "66",
                    "ref_id": "BIBREF54"
                }
            ],
            "ref_spans": [],
            "section": "Triple-combination antiviral drug (TCAD) treatment"
        },
        {
            "text": "In a small cohort of highly immunocompromised patients infected with infl uenza, TCAD recipients did not have emergence of resistance-associated substitutions; the regimen was reasonably well tolerated over 10 days and provided the target blood concentrations of the individual drugs. 80 A retrospective observational study of critically ill adults infected with pandemic H1N1 virus suggest non-signifi cant trends towards reduced 14 day (17% vs 35%; p=0\u00b708) and 90 day (46% vs 59%; p=0\u00b723) mortality in TCAD recipients compared with those receiving oseltamivir monotherapy. 81 A randomised controlled trial trial sponsored by the National Institute of Allergy and Infectious Disease comparing TCAD with oseltamivir monotherapy for ambulatory high-risk patients is in progress (NCT01227967), and controlled studies in hospital inpatients seem to be warranted.",
            "cite_spans": [
                {
                    "start": 285,
                    "end": 287,
                    "text": "80",
                    "ref_id": "BIBREF68"
                },
                {
                    "start": 575,
                    "end": 577,
                    "text": "81",
                    "ref_id": "BIBREF69"
                }
            ],
            "ref_spans": [],
            "section": "Triple-combination antiviral drug (TCAD) treatment"
        },
        {
            "text": "Favipiravir or T-705 (Toyama Chemical Co, Tokyo, Japan) is a novel infl uenza polymerase inhibitor that is active against infl uenza A, B, and C viruses including adamantane-resistant or oseltamivir-resistant variants. 82 Favipiravir and oseltamivir show concentration-related additive or synergistic eff ects for infl uenza A viruses in vitro and, depending on dose and timing, on survival in mice infected with various infl uenza viruses. 83 Combination of suboptimum doses of favipiravir and oseltamivir aff orded 60-80% protection and improved bodyweights during infection in a lethal H5N1 model (one designed to give an infectious dose that is predictably associated with 100% mortality, and combinations of favipiravir and peramivir also showed synergy in survival and enhanced antiviral eff ects compared with suboptimum doses of each compound alone for the treatment of 2009 pandemic H1N1 virus in mice. 84 Limited testing has recorded no pharmacokinetic interactions of oral favipiravir and oseltamivir in healthy participants. However, dose adjustments in the setting of renal insuffi ciency are still to be identifi ed, and the recommended dose regimen varies with the target population (Asian and white). In Japan, where favipiravir has been approved for treatment of novel or re-emerging infl uenza virus infections (limited to cases in which other anti-infl uenza virus drugs are ineff ective or not suffi ciently eff ective), 85 a phase 3 study in uncomplicated infl uenza showed similar antiviral eff ects as oseltamivir. 86 A phase 2 treatment study completed in adults reported evidence for symptom alleviation, 87 and a large phase 3 randomised controlled trial in uncomplicated disease was initiated during the 2013-14 season (NCT02008344). In view of the available preclinical data, oral favipiravir would be an especially interesting candidate for study of combination therapy with a neuraminidase inhibitor in serious infl uenza viral infection.",
            "cite_spans": [
                {
                    "start": 219,
                    "end": 221,
                    "text": "82",
                    "ref_id": "BIBREF70"
                },
                {
                    "start": 441,
                    "end": 443,
                    "text": "83",
                    "ref_id": "BIBREF71"
                },
                {
                    "start": 912,
                    "end": 914,
                    "text": "84",
                    "ref_id": "BIBREF72"
                },
                {
                    "start": 1538,
                    "end": 1540,
                    "text": "86",
                    "ref_id": "BIBREF74"
                },
                {
                    "start": 1630,
                    "end": 1632,
                    "text": "87",
                    "ref_id": "BIBREF75"
                }
            ],
            "ref_spans": [],
            "section": "Favipiravir"
        },
        {
            "text": "plasma containing virus-specifi c neutralising antibodies has been used with apparent benefi t in neuraminidase inhibitor-treated patients with severe H5N1 infection. 88 In a cohort study in neuraminidase inhibitor-treated, critically ill patients infected with 2009 pandemic H1N1 virus, crude mortality was reduced from 55% in non-treated patients to 20% in 20 patients receiving convalescent plasma (p=0\u00b7011), and substantial reductions in nasopharyngeal viral load (quantity of viral RNA copy number in volume of sample) on treatment days 3-7 and in plasma cytokines and chemokines were recorded compared with controls. 45 In a similar critically ill group of patients receiving neuraminidase inhibitor therapy, a small double-blind Review randomised controlled trial of hyperimmune globulin containing high neutralising antibody titres to infl uenza pandemic H1N1 virus was associated with no mortality when treatment was given within 5 days of illness onset compared with 40% in those receiving pre-2009 intravenous immunoglobulin (p=0\u00b704), 89 although overall mortality did not diff er between the groups when those with delayed administration were included (fi ve of 17 treated and four of 17 untreated). These fi ndings suggest that the combination of neuraminidase inhibitor therapy with neutralising antibodies in the form of convalescent plasma or hyperimmune globin would be an appropriate choice for study in patients with severe H7N9 illness once available.",
            "cite_spans": [
                {
                    "start": 167,
                    "end": 169,
                    "text": "88",
                    "ref_id": "BIBREF76"
                },
                {
                    "start": 623,
                    "end": 625,
                    "text": "45",
                    "ref_id": "BIBREF33"
                },
                {
                    "start": 1046,
                    "end": 1048,
                    "text": "89",
                    "ref_id": "BIBREF77"
                }
            ],
            "ref_spans": [],
            "section": "Convalescent"
        },
        {
            "text": "Broad-spectrum neutralising monoclonal antibodies that target conserved epitopes on the stem of viral haemagglutinin and inhibit fusion have therapeutic activity in animal models of infl uenza for group 1 haemagglutinins (including H1, H2, H5, and H9), 90 group 2 haemagglutinins (including H3 and H7), 91 or both group 1 and 2 haemagglutinins. 92 One pan-infl uenza anti haemag glutinin stem monoclonal antibody (designated 39.29) increased survival in mice infected with A/PR/8/34 H1N1] virus when combined with oseltamivir compared with either single agent. 93 These antibodies are just entering clinical trials at present but might off er broad-spectrum activity, especially if they possess suffi cient avidity and can be delivered in suffi cient quantity.",
            "cite_spans": [
                {
                    "start": 253,
                    "end": 255,
                    "text": "90",
                    "ref_id": "BIBREF78"
                },
                {
                    "start": 345,
                    "end": 347,
                    "text": "92",
                    "ref_id": "BIBREF80"
                },
                {
                    "start": 561,
                    "end": 563,
                    "text": "93",
                    "ref_id": "BIBREF81"
                }
            ],
            "ref_spans": [],
            "section": "Convalescent"
        },
        {
            "text": "Several antivirals that possess novel mechanisms of action and show anti-infl uenza activity in initial clinical studies would also be options for potential combination regimens with neuraminidase inhibitors or other approved drugs. 28, 94 Nitazoxanide is an approved oral antiparasitic agent with a well defi ned safety profi le and human pharma cology. In vitro, nitazoxanide and its active metabolite tizoxanide inhibit infl uenza virus replication at submicromolar concentrations. 95, 96 Nitazoxanide is reportedly both an interferon inducer and an inhibitor of infl uenza antihaemagglutinin maturation through a novel mechanism of action. 97 Scarce in-vitro testing shows evidence for synergy with combinations of tizoxanide and neuraminidase inhibitors in preclinical testing. 96 A placebo-controlled phase 2 randomised controlled trial in uncomplicated infl uenza showed great antiviral eff ects and clinical benefi t (roughly a 21 h reduction in illness duration) at a dose of 600 mg twice a day compared with placebo. 98 Under the sponsorship of the Biomedical Advanced Research and Development Authority (BARDA), a large phase 3 randomised placebo-controlled trial has been initiated to compare nitazoxanide mono therapy, oseltamivir monotherapy, and the combination of oseltamivir and nitazoxanide for the treatment of uncomplicated infl uenza (NCT01610245).",
            "cite_spans": [
                {
                    "start": 233,
                    "end": 236,
                    "text": "28,",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 237,
                    "end": 239,
                    "text": "94",
                    "ref_id": "BIBREF82"
                },
                {
                    "start": 485,
                    "end": 488,
                    "text": "95,",
                    "ref_id": "BIBREF83"
                },
                {
                    "start": 489,
                    "end": 491,
                    "text": "96",
                    "ref_id": "BIBREF84"
                },
                {
                    "start": 644,
                    "end": 646,
                    "text": "97",
                    "ref_id": "BIBREF86"
                },
                {
                    "start": 783,
                    "end": 785,
                    "text": "96",
                    "ref_id": "BIBREF84"
                },
                {
                    "start": 1027,
                    "end": 1029,
                    "text": "98",
                    "ref_id": "BIBREF88"
                }
            ],
            "ref_spans": [],
            "section": "Other investigational antiviral drugs"
        },
        {
            "text": "Inhaled DAS181 (Ansun Biopharma, San Diego, CA, USA) is a conjugated sialidase that destroys the sialic acidbearing receptors on host cells that are used by infl uenza A and B and parainfl uenza viruses, to initiate infection. Topically applied DAS181 is active in murine and ferret models of infl uenza including H5N1, H7N9, and other infl uenza viruses. 55, 99, 100 Because of its novel host-directed mechanism of action, DAS181 is active against viruses resistant to existing agents 99,101 and has a low risk of resistance emergence. Longlasting in-vitro passage of infl uenza viruses in the presence of DAS181 leads to emergence of unstable variants with three to 18-fold reductions in susceptibility that contain substitutions in antihaemagglutinin and neuroaminidase. 102 Inhaled DAS181 showed great antiviral eff ects in a phase 2 randomised controlled trial in uncomplicated infl uenza, although no demonstrable eff ects on illness resolution. 103 The inhalation route might prove diffi cult in severe illness, but several case reports have shown apparent clinical benefi t and no serious adverse events when used for treatment of serious parainfl uenza virus in immunocompromised hosts. 104, 105 Further studies in uncomplicated infl uenza are in progress (NCT01740063).",
            "cite_spans": [
                {
                    "start": 356,
                    "end": 359,
                    "text": "55,",
                    "ref_id": "BIBREF43"
                },
                {
                    "start": 360,
                    "end": 363,
                    "text": "99,",
                    "ref_id": "BIBREF90"
                },
                {
                    "start": 364,
                    "end": 367,
                    "text": "100",
                    "ref_id": "BIBREF91"
                },
                {
                    "start": 774,
                    "end": 777,
                    "text": "102",
                    "ref_id": "BIBREF93"
                },
                {
                    "start": 952,
                    "end": 955,
                    "text": "103",
                    "ref_id": "BIBREF94"
                },
                {
                    "start": 1196,
                    "end": 1200,
                    "text": "104,",
                    "ref_id": "BIBREF95"
                },
                {
                    "start": 1201,
                    "end": 1204,
                    "text": "105",
                    "ref_id": "BIBREF96"
                }
            ],
            "ref_spans": [],
            "section": "Other investigational antiviral drugs"
        },
        {
            "text": "Arbidol is an oral antiviral available used for infl uenza treatment in Russia (where it has been available over-thecounter since 1990) and some other countries. 106 It has broad spectrum inhibitory eff ects for many enveloped RNA viruses, but also specifi cally targets infl uenza antihaemagglutinin-mediated membrane fusion. Arbidol-resistant variants selected in vitro have substitutions in the antihaemagglutinin 2 subunit. 107 Arbidol shows dose-related antiviral eff ects and survival in murine model studies, 108 and experiments in cell culture have shown synergistic eff ects when combined with adamantanes, ribavirin, or neuraminidase inhibitors. 106, 109 Few randomised controlled trial data on its clinical and antiviral effi cacy are available, but it seems to be generally well tolerated when used for infl uenza prophylaxis or treatment in Russian studies, and further studies are in progress. Arbidol would be an interesting candidate for combination studies, particularly in countries where it is already being used as monotherapy.",
            "cite_spans": [
                {
                    "start": 162,
                    "end": 165,
                    "text": "106",
                    "ref_id": "BIBREF97"
                },
                {
                    "start": 428,
                    "end": 431,
                    "text": "107",
                    "ref_id": "BIBREF98"
                },
                {
                    "start": 516,
                    "end": 519,
                    "text": "108",
                    "ref_id": "BIBREF99"
                },
                {
                    "start": 656,
                    "end": 660,
                    "text": "106,",
                    "ref_id": "BIBREF97"
                },
                {
                    "start": 661,
                    "end": 664,
                    "text": "109",
                    "ref_id": "BIBREF100"
                }
            ],
            "ref_spans": [],
            "section": "Other investigational antiviral drugs"
        },
        {
            "text": "Oral VX-787 (Vertex Pharmaceuticals, Boston, MA, USA) has a novel mechanism of action selective for infl uenza A viruses and is active against neuraminidaseinhibitor variants and adamantane-resistant variants and would probably show enhanced activity in combination with neuroaminidase inhibitors. Oral VX-787 is reported to have positive antiviral and clinical eff ects in a phase 2 experimental infection study in human beings at highest dose tested of 1200 mg once, followed by 600 mg daily for 4 days. 110 AVI-7100 (Serepta, Cambridge, MA) is a smallinterfering RNA (siRNA) construct designed to inhibit the translation of both the matrix protein and the M2 ion channel by targeting their shared translation initiation start site. 111, 112 This modifi ed phosphorodiamidate Review morpholino oligomer has enhanced resistance to enzymatic degradation, improves pharmacological properties, and limits the potential for non-specifi c immuno modulatory eff ects. Ferret studies with an oseltamivir-resistant H1N1 virus have shown disease moderation and reduced viral titres after topical or intraperitoneal administration, including reduced transmission in ferrets after intranasal administration. 111, 112 Although oseltamivir was not inhibitory in this model, the combination of intranasal or intraperitoneal AVI-7100 with oral oseltamivir tended to reduce nasal viral titres to greater extent than AVI-7100 alone. 111 The National Institute of Allergy and Infectious Disease is conducting a phase 1, randomised placebo-controlled trial to assess the safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous AVI-7100 in healthy participants (NCT01747148).",
            "cite_spans": [
                {
                    "start": 506,
                    "end": 509,
                    "text": "110",
                    "ref_id": "BIBREF101"
                },
                {
                    "start": 735,
                    "end": 739,
                    "text": "111,",
                    "ref_id": "BIBREF102"
                },
                {
                    "start": 740,
                    "end": 743,
                    "text": "112",
                    "ref_id": "BIBREF103"
                },
                {
                    "start": 1198,
                    "end": 1202,
                    "text": "111,",
                    "ref_id": "BIBREF102"
                },
                {
                    "start": 1203,
                    "end": 1206,
                    "text": "112",
                    "ref_id": "BIBREF103"
                },
                {
                    "start": 1417,
                    "end": 1420,
                    "text": "111",
                    "ref_id": "BIBREF102"
                }
            ],
            "ref_spans": [],
            "section": "Other investigational antiviral drugs"
        },
        {
            "text": "Several potential immunomodulatory agents have been proposed for adjunctive infl uenza treatment, mainly those directed against excessive proinfl ammatory host responses to infection. 27, 28, 113, 114 Many of these have shown activity in animal models and new candidates, such as the agonist of human complement component 5a (C5a) termed EP67, 115 the retinoic acidinducible gene 1 (RIG-I) agonist 5\u02b9triphosphate RNA, 116 and the Toll-like receptor 4 antagonist Eritoran (EisaiCo, Tokyo, Japan) 117 continue to be reported. For example, studies suggest that the endogenous lipid mediator protectin D1 is downregulated during severe infl uenza and that exogenous administration exerts antiviral eff ects and improves outcome from severe infl uenza in a mouse model. 118 Agents with dual mechanisms of action have also been described: the cyclo-oxygenase 2 (COX-2) inhibitor naproxen was shown to inhibit infl uenza nucleoprotein and exert antiviral eff ects in a murine model. 119 Depending on the particular model, drugs with either proinfl ammatory or anti-infl ammatory eff ects have shown benefi ts in animal models. However, few immunomodulators have been studied in combination with infl uenza antivirals in preclinical studies, and none have been studied in adequately powered randomised controlled trials in serious human infl uenza (appendix). Furthermore, the unclear relation of disease pathogenesis in animal models, especially murine ones, with human infl uenza, and the heterogeneity of factors contributing to severe human infl uenza, 120 means that the predictive value of immunomodulator activity in animal models of infl uenza studies is unclear. One obvious concern is that downregulation of important innate immune responses could contribute to inadequate control of viral replication and be associated with worsened clinical outcomes.",
            "cite_spans": [
                {
                    "start": 184,
                    "end": 187,
                    "text": "27,",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 188,
                    "end": 191,
                    "text": "28,",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 192,
                    "end": 196,
                    "text": "113,",
                    "ref_id": "BIBREF104"
                },
                {
                    "start": 197,
                    "end": 200,
                    "text": "114",
                    "ref_id": "BIBREF105"
                },
                {
                    "start": 344,
                    "end": 347,
                    "text": "115",
                    "ref_id": "BIBREF106"
                },
                {
                    "start": 418,
                    "end": 421,
                    "text": "116",
                    "ref_id": "BIBREF107"
                },
                {
                    "start": 765,
                    "end": 768,
                    "text": "118",
                    "ref_id": "BIBREF109"
                },
                {
                    "start": 976,
                    "end": 979,
                    "text": "119",
                    "ref_id": "BIBREF110"
                }
            ],
            "ref_spans": [],
            "section": "Antiviral and immunomodulator combinations"
        },
        {
            "text": "However, some immunomodulatory agents such as the mammalian target of rapamycin (mTOR) inhibitors 121 or inhibitors of the Raf-MEK-ERK pathway 122 seem to target host cell pathways essential for viral replication. The mTOR inhibitor everolimus shows antiviral eff ects and disease mitigation in a lethal murine model of infl uenza. 121 A small, open-label randomised controlled trial in critically ill adults infected with 2009 pandemic H1N1 virus pjp who were all given oral oseltamivir and systemic corticosteroids showed both more rapid improvements in respiratory function (as shown in parameters of gas exchange and need for mechanical ventilation) and reduced viral detection on day 7 in recipients of the mTOR inhibitor sirolimus compared with no treatment, although there was no overall diff erence in mortality. 46 The potential value of mTOR inhibitors in severe infl uenza warrants further study. Immunomodulatory agents that have increased survival in combination with infl uenza antivirals in murine models include N-acetylcysteine, 123,124 a topical sphingosine analogue designated AAL-R that inhibits various proinfl ammatory cytokine and chemokine responses, 125 the COX-2 inhibitor celecoxib with mesalazine, 126 thymosin, 127 topical surfactant, 128 and probenecid. 129 In addition to the enhanced antiviral activity reported with combined probenecid and oseltamivir treatment in a mouse model of infl uenza, 129 this combination is particularly interesting since probenecid inhibits oseltamivir carboxylate excretion and potentially enables either boosting of blood concentrations or dosing-sparing. 130",
            "cite_spans": [
                {
                    "start": 98,
                    "end": 101,
                    "text": "121",
                    "ref_id": "BIBREF112"
                },
                {
                    "start": 332,
                    "end": 335,
                    "text": "121",
                    "ref_id": "BIBREF112"
                },
                {
                    "start": 821,
                    "end": 823,
                    "text": "46",
                    "ref_id": null
                },
                {
                    "start": 1226,
                    "end": 1229,
                    "text": "126",
                    "ref_id": "BIBREF117"
                },
                {
                    "start": 1264,
                    "end": 1267,
                    "text": "128",
                    "ref_id": "BIBREF119"
                },
                {
                    "start": 1284,
                    "end": 1287,
                    "text": "129",
                    "ref_id": "BIBREF120"
                },
                {
                    "start": 1427,
                    "end": 1430,
                    "text": "129",
                    "ref_id": "BIBREF120"
                }
            ],
            "ref_spans": [],
            "section": "Antiviral and immunomodulator combinations"
        },
        {
            "text": "The use of widely available, low cost drugs with immunomodulatory activity has been promoted as a possible treatment strategy, 114 but so far no prospective randomised controlled trials of such agents have been completed in patients with severe infl uenza illness. In mice infected with avian H5N1 virus, simvastatin given with oseltamivir did not improve the effi cacy of oseltamivir monotherapy, 131 whereas a preliminary study reported some disease-modifying eff ects with a triple regimen of osetltamivir, simvastatin, and fenofi brate compared with oseltamivir alone. 132 Observational studies from the 2009 pandemic did not fi nd improved outcomes in severely ill patients given neuraminidase inhibitors and various immunomodulatory therapies including macrolides and statins. 133 One retrospective analysis in uncomplicated infl uenza did not fi nd that the addition of clarithromycin to oseltamivir improved clinical outcomes. 134 In a prospective observational study of critically ill patients with infl uenza without evidence of bacterial co-infection, treatment with macrolides was not associated with improved survival. 135 However, several retrospective studies have reported substantial mortality benefi ts in patients taking statins who were subsequently admitted to hospital for seasonal infl uenza 136 or pneumonia. 137, 138 Other studies have not shown such results, and the possible benefi t of starting statins at the time of infl uenza onset or treatment in Review hospital has not been reported. One randomised controlled trial in an intensive care unit suggested reduced risks of ventilator-associated pneumonia and mortality with addition of pravastatin therapy in patients needing mechanical ventilation; 139 further studies are warranted.",
            "cite_spans": [
                {
                    "start": 398,
                    "end": 401,
                    "text": "131",
                    "ref_id": "BIBREF122"
                },
                {
                    "start": 573,
                    "end": 576,
                    "text": "132",
                    "ref_id": "BIBREF123"
                },
                {
                    "start": 783,
                    "end": 786,
                    "text": "133",
                    "ref_id": "BIBREF124"
                },
                {
                    "start": 935,
                    "end": 938,
                    "text": "134",
                    "ref_id": "BIBREF125"
                },
                {
                    "start": 1132,
                    "end": 1135,
                    "text": "135",
                    "ref_id": "BIBREF126"
                },
                {
                    "start": 1333,
                    "end": 1337,
                    "text": "137,",
                    "ref_id": "BIBREF128"
                },
                {
                    "start": 1338,
                    "end": 1341,
                    "text": "138",
                    "ref_id": "BIBREF129"
                }
            ],
            "ref_spans": [],
            "section": "Macrolides and statins"
        },
        {
            "text": "Interferon alfa shows enhanced anti-infl uenza activity in vitro with other antivirals, 29, 34 in addition to its immunomodulatory properties. Some evidence shows that severely ill patients with infl uenza have defi cient endogenous interferon responses. 140, 141 Systemic interferon is active in a murine model of H5N1 virus infection 142 and in a macaque model of H1N1 virus infection. 143 Systemic interferon-alfacon-1 in combination with systemic glucocorticoids showed possible benefi t and adequate tolerance in treatment of patients with severe acute respiratory syndrome coronavirus, (SARS) infection 144 but systemic interferon has not been studied in serious infl uenza until now.",
            "cite_spans": [
                {
                    "start": 88,
                    "end": 91,
                    "text": "29,",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 92,
                    "end": 94,
                    "text": "34",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 255,
                    "end": 259,
                    "text": "140,",
                    "ref_id": "BIBREF131"
                },
                {
                    "start": 260,
                    "end": 263,
                    "text": "141",
                    "ref_id": "BIBREF132"
                },
                {
                    "start": 336,
                    "end": 339,
                    "text": "142",
                    "ref_id": "BIBREF133"
                },
                {
                    "start": 388,
                    "end": 391,
                    "text": "143",
                    "ref_id": "BIBREF134"
                },
                {
                    "start": 609,
                    "end": 612,
                    "text": "144",
                    "ref_id": "BIBREF135"
                }
            ],
            "ref_spans": [],
            "section": "Interferons"
        },
        {
            "text": "Systemic glucocorticoids have been frequently used for treatment of infl uenza-associated pneumonia and acute respiratory distress syndrome (ARDS), including up to 60% of hospital inpatients with avian infl uenza A H7N9 illness. 23 Almost all of these patients have been given concurrent antiviral therapy. However, extension of viral replication has been identifi ed in patients with seasonal infl uenza given systemic glucocorticoids for management of chronic obstructive pulmonary disease or asthma, 145 and large observational studies from the 2009 pandemic reported that systemic glucocorticoid administration for pneumonia or ARDS was associated with increases in secondary bacterial and fungal infections, prolongation of intensive care unit stay, and sometimes higher mortality in intensive care unit patients. [146] [147] [148] [149] Reports of patients infected with H7N9 virus suggest that glucocorticoid use might also be a risk factor for antiviral resistance emergence. 17, 56 Consequently, their use for infl uenzaassociated pneumonia or ARDS should best be limited to controlled clinical studies.",
            "cite_spans": [
                {
                    "start": 229,
                    "end": 231,
                    "text": "23",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 503,
                    "end": 506,
                    "text": "145",
                    "ref_id": "BIBREF136"
                },
                {
                    "start": 819,
                    "end": 824,
                    "text": "[146]",
                    "ref_id": "BIBREF137"
                },
                {
                    "start": 825,
                    "end": 830,
                    "text": "[147]",
                    "ref_id": "BIBREF138"
                },
                {
                    "start": 831,
                    "end": 836,
                    "text": "[148]",
                    "ref_id": "BIBREF139"
                },
                {
                    "start": 837,
                    "end": 842,
                    "text": "[149]",
                    "ref_id": "BIBREF140"
                },
                {
                    "start": 984,
                    "end": 987,
                    "text": "17,",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 988,
                    "end": 990,
                    "text": "56",
                    "ref_id": "BIBREF44"
                }
            ],
            "ref_spans": [],
            "section": "Glucocorticoids"
        },
        {
            "text": "The use of CTMs in the treatment of seasonal infl uenza has a history of several thousands of years. 150 The mechanisms of CTMs in the treatment of infl uenza are complex and incompletely understood. Maxingshigan, one formulation of CTM, directly inactivates infl uenza A virus, idisrupting adsorption, and protecting cells from becoming infected. The administration of Chinese herbs might also have benefi cial immunomodulatory eff ects, but few clinical trials have been reported about the eff ects of combination therapy in infl uenza. One multicentre, prospective nonblinded randomised controlled trial compared the effi cacy and safety of oseltamivir, maxingshigan-yinqiaosan, and the combination of both in treatment of outpatients with 2009 pandemic infl uenza A. 151 ",
            "cite_spans": [
                {
                    "start": 101,
                    "end": 104,
                    "text": "150",
                    "ref_id": "BIBREF141"
                },
                {
                    "start": 771,
                    "end": 774,
                    "text": "151",
                    "ref_id": "BIBREF142"
                }
            ],
            "ref_spans": [],
            "section": "Chinese traditional medicine (CTM)"
        },
        {
            "text": "The primary searches for relevant studies for inclusion were done through PubMed between Jan 1, 1994 and May 1, 2014, in English with the following disease terms: \"infl uenza\" or \"infl uenza, human\". The results of these searches were crossed with the drug terms \"interferons\" or \"oseltamivir\" or \"zanamivir\" or \"neuraminidase inhibitor\" or \"amantadine\" or \"peramivir\" or \"rimantadine\" or \"ribavirin\" or \"vaccines, combined\" or \"drug therapy, combination\" or \"combined drug therapy\" or \"combined antiviral therapy\" or \"antiviral therapy\", and the identifi ed abstracts were screened by one or more researchers. Earlier studies were also identifi ed from the fi les of the senior author. We focused on studies of approved drugs and those in active clinical development that might be considered for near-term clinical study or use in combinations. Articles that studied investigational drugs that had not progressed in development (eg, in-vitro studies of plant extracts) or were inaccessible because of language barriers were not included. In addition, we searched three Chinese databases: Sinomed (former Chinese Biomedical Literature Database); China Knowledge Resource Integrated Database; and the WANFANG Database.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Search strategies and selection criteria"
        },
        {
            "text": "Observational clinical studies with no control groups or those without laboratoryconfi rmed infl uenza virus detection were not included.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Search strategies and selection criteria"
        },
        {
            "text": "involving CTMs (appendix) have had limitations with respect to clarity on study methods (ie, randomisation procedures, blinding, and placebo controls) and adequacy of adverse-event reporting.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Search strategies and selection criteria"
        },
        {
            "text": "Because of the many potential combinations that might be considered for study, various criteria need to be thought about to select the most appropriate interventions to take forward into clinical testing (table 2) . For example, based on the availability in China at present, antiviral combinations of oseltamivir or intravenous peramivir with ribavirin, convalescent plasma, or some other form of neutralising antibody, or perhaps with nitazoxanide would be candidates for testing in serious infl uenza illness including that caused by avian H7N9. 56 Likewise, the strategies for clinical testing will need careful consideration. Since doing randomised controlled trials in seriously ill hospital inpatients is particularly diffi cult and resource intensive, 120 initial proof-of-concept studies might be done in alternative populations such experimentally infected volunteers 152 or outpatients with infl uenza. For antiviral combinations, the initial goal is to show tolerability and greater antiviral eff ects than with monotherapy. Consequently, smaller clinical studies that examine virological endpoints (quantitative virology and resistance emergence) might suffi ce to fi nd out which combinations to take forward into large studies in risk groups or hospital inpatients. For combinations involving immunomodulatory interventions, the challenges are great because the goal is disease amelioration through modulation of host responses. Unfortunately, our understanding of the heterogeneity and dynamics of immune responses in serious human infl uenza and their relation to disease pathogenesis is limited. The possibility of using immunomodulatory interventions will need to consider the particular target population and disease stage, the goa l of either suppressing adverse host responses or supplementing defi cient ones, and the timing of initiating and ceasing the intervention in relation to the course of illness. Adaptive clinical trial designs off er greater fl exibility and effi ciency through planned modifi cations, such as changes to sample size and treatment arms based on statistical analysis of data generated in the early stages of a trial. 153 By incorporating objective endpoints, such designs would enable the study of several diff erent combinations simultaneously.",
            "cite_spans": [
                {
                    "start": 549,
                    "end": 551,
                    "text": "56",
                    "ref_id": "BIBREF44"
                },
                {
                    "start": 2167,
                    "end": 2170,
                    "text": "153",
                    "ref_id": "BIBREF144"
                }
            ],
            "ref_spans": [
                {
                    "start": 204,
                    "end": 213,
                    "text": "(table 2)",
                    "ref_id": "TABREF3"
                }
            ],
            "section": "Future directions"
        },
        {
            "text": "FGH conceived the Review and wrote the fi rst draft. JD reviewed the scientifi c literature on combination antiviral therapy, developed the associated appendix, and provided key revisions to the text. JKB reviewed the scientifi c literature on combination antiviral and immunomodulatory therapy, developed the associated appendix, and provided key revisions to the text. BC reviewed the scientifi c literature on combinations involving traditional Chinese medicine and provided associated updates to the appendices and text. All authors contributed to editing the fi nal draft of the Review and all authors approved the fi nal version.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Contributors"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Eff ectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with infl uenza A H1N1pdm09 virus infection: a metaanalysis of individual participant data",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "G"
                    ],
                    "last": "Muthuri",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Venkatesan",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "R"
                    ],
                    "last": "Myles",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Lancet Respir Med",
            "volume": "2",
            "issn": "",
            "pages": "395--404",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Determinants of antiviral eff ectiveness in infl uenza virus A subtype H5N1",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "K"
                    ],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Zaman",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Infect Dis",
            "volume": "206",
            "issn": "",
            "pages": "1359--66",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Fatal cases of pandemic (H1N1) 2009 infl uenza despite their early antiviral treatment in Japan",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Nukiwa",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Kamigaki",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Oshitani",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Clin Infect Dis",
            "volume": "51",
            "issn": "",
            "pages": "993--94",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Association between adverse clinical outcome in human disease caused by novel infl uenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Lancet",
            "volume": "381",
            "issn": "",
            "pages": "2273--79",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 infl uenza virus infection",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "K"
                    ],
                    "last": "To",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "F"
                    ],
                    "last": "Hung",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "W"
                    ],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Clin Infect Dis",
            "volume": "50",
            "issn": "",
            "pages": "850--59",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Diagnosis, management and outcomes of adults hospitalized with infl uenza",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Ison",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Antivir Ther",
            "volume": "17",
            "issn": "",
            "pages": "143--57",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Pandemic infl uenza A(H1N1) 2009: molecular characterisation and duration of viral shedding in intensive care patients in",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Malato",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Llavador",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Marmier",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Euro Surveill",
            "volume": "16",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Antiviral resistance during the 2009 infl uenza A H1N1 pandemic: public health, laboratory, and clinical perspectives",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Hurt",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Chotpitayasunondh",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "J"
                    ],
                    "last": "Cox",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Lancet Infect Dis",
            "volume": "12",
            "issn": "",
            "pages": "240--288",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Oseltamivir resistance during treatment of infl uenza A (H5N1) infection",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "De Jong",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "T"
                    ],
                    "last": "Tran",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "K"
                    ],
                    "last": "Truong",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "N Engl J Med",
            "volume": "353",
            "issn": "",
            "pages": "2667--72",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Clinical fi ndings in 111 cases of infl uenza A (H7N9) virus infection",
            "authors": [
                {
                    "first": "H",
                    "middle": [
                        "N"
                    ],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "Z"
                    ],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "N Engl J Med",
            "volume": "368",
            "issn": "",
            "pages": "2277--85",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Combination antiviral therapy for infl uenza: predictions from modeling of human infections",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Perelson",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Rong",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Infect Dis",
            "volume": "205",
            "issn": "",
            "pages": "1642--1687",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Asymptomatic ratio for seasonal H1N1 infl uenza infection among schoolchildren in Taiwan",
            "authors": [
                {
                    "first": "Y",
                    "middle": [
                        "H"
                    ],
                    "last": "Hsieh",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "A"
                    ],
                    "last": "Tsai",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "Y"
                    ],
                    "last": "Lin",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "BMC Infect Dis",
            "volume": "14",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against infl uenza virus infections",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ludwig",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Biol Chem",
            "volume": "392",
            "issn": "",
            "pages": "837--884",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Combinations of antiviral agents for treatment of infl uenza virus infections",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                }
            ],
            "year": 1986,
            "venue": "J Antimicrob Chemother",
            "volume": "18",
            "issn": "",
            "pages": "177--83",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Newer infl uenza antivirals, biotherapeutics and combinations",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Infl uenza Other Respir Viruses",
            "volume": "",
            "issn": "7",
            "pages": "63--75",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Combined inhibition of infl uenza virus reproduction in cell culture using interferon and amantadine",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "V"
                    ],
                    "last": "Lavrov",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "I"
                    ],
                    "last": "Eremkina",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "G"
                    ],
                    "last": "Orlova",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Galegov",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "D"
                    ],
                    "last": "Soloviev",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "M"
                    ],
                    "last": "Zhdanov",
                    "suffix": ""
                }
            ],
            "year": 1968,
            "venue": "Nature",
            "volume": "217",
            "issn": "",
            "pages": "856--57",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Combined action of ribovirin and rimantadine in experimental myxovirus infection",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Galegov",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "L"
                    ],
                    "last": "Pushkarskaya",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "P"
                    ],
                    "last": "Obrosova-Serova",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "M"
                    ],
                    "last": "Zhdanov",
                    "suffix": ""
                }
            ],
            "year": 1977,
            "venue": "Experientia",
            "volume": "33",
            "issn": "",
            "pages": "905--911",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Amantadine and ribavirin aerosol treatment of infl uenza A and B infection in mice",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "Z"
                    ],
                    "last": "Wilson",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Knight",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "R"
                    ],
                    "last": "Wyde",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Drake",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "B"
                    ],
                    "last": "Couch",
                    "suffix": ""
                }
            ],
            "year": 1980,
            "venue": "Antimicrob Agents Chemother",
            "volume": "17",
            "issn": "",
            "pages": "642--690",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Prevention of the formation of a mutant infl uenza A virus resistant to rimantadine (alpha-methyl-1-adamantanemethylamine hydrochloride) by using ribavirin",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "L"
                    ],
                    "last": "Pushkarskaia",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Nd",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Galegov",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant infl uenza A variants",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "A"
                    ],
                    "last": "Ilyushina",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "V"
                    ],
                    "last": "Bovin",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Webster",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Govorkova",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Antiviral Res",
            "volume": "70",
            "issn": "",
            "pages": "121--152",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of infl uenza virus replication in vitro",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "N"
                    ],
                    "last": "Schlepushkin",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "L"
                    ],
                    "last": "Pushkarskaya",
                    "suffix": ""
                }
            ],
            "year": 1984,
            "venue": "Antimicrob Agents Chemother",
            "volume": "25",
            "issn": "",
            "pages": "53--57",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Amantadine-oseltamivir combination therapy for H5N1 infl uenza virus infection in mice",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "A"
                    ],
                    "last": "Ilyushina",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Hoff Mann",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Salomon",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Webster",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Govorkova",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Antivir Ther",
            "volume": "12",
            "issn": "",
            "pages": "363--70",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is effi cacious against A/Hong Kong/156/97 (H5N1) and A/Hong",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "A"
                    ],
                    "last": "Leneva",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Roberts",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Govorkova",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [
                        "G"
                    ],
                    "last": "Goloubeva",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Webster",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "(H9N2) infl uenza viruses",
            "authors": [],
            "year": 2000,
            "venue": "Antiviral Res",
            "volume": "48",
            "issn": "",
            "pages": "101--116",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-infl uenza virus eff ects in MDCK cells",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Govorkova",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "B"
                    ],
                    "last": "Fang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Tan",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Webster",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Antimicrob Agents Chemother",
            "volume": "48",
            "issn": "",
            "pages": "4855--63",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Rimantadine and oseltamivir demonstrate synergistic combination eff ect in an experimental infection with type A (H3N2) infl uenza virus in mice",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Galabov",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Simeonova",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Gegova",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Antivir Chem Chemother",
            "volume": "17",
            "issn": "",
            "pages": "251--58",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Combination of peramivir and rimantadine demonstrate synergistic antiviral eff ects in sub-lethal infl uenza A (H3N2) virus mouse model",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bantia",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Kellogg",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "D"
                    ],
                    "last": "Parker",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "S"
                    ],
                    "last": "Babu",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Antiviral Res",
            "volume": "88",
            "issn": "",
            "pages": "276--80",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "In vitro inhibitory eff ects of combinations of anti-infl uenza agents",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "K"
                    ],
                    "last": "Madren",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Shipman",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "Antivir Chem & Chemother",
            "volume": "2",
            "issn": "",
            "pages": "109--122",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Safety and effi cacy of nebulized zanamivir in hospitalized patients with serious infl uenza",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Ison",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "W"
                    ],
                    "last": "Gnann",
                    "suffix": ""
                },
                {
                    "first": "Jr",
                    "middle": [],
                    "last": "Nagy-Agren",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Antivir Ther",
            "volume": "8",
            "issn": "",
            "pages": "183--90",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Effi cacy of oseltamivirzanamivir combination compared to each monotherapy for seasonal infl uenza: a randomized placebo-controlled trial",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Duval",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "S"
                    ],
                    "last": "Van Der",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Blanchon",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "PLoS Med",
            "volume": "7",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Atiee",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Lasseter",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Baughman",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Clin Pharmacol",
            "volume": "52",
            "issn": "",
            "pages": "1410--1429",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Pukrittayakamee",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Jittamala",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Stepniewska",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Antimicrob Agents Chemother",
            "volume": "55",
            "issn": "",
            "pages": "4050--57",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Convalescent plasma treatment reduced mortality in patients with severe pandemic infl uenza A (H1N1) 2009 virus infection",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "F"
                    ],
                    "last": "Hung",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "K"
                    ],
                    "last": "To",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "K"
                    ],
                    "last": "Lee",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Clin Infect Dis",
            "volume": "52",
            "issn": "",
            "pages": "447--56",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "H"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "T"
                    ],
                    "last": "Chung",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Lin",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Crit Care Med",
            "volume": "42",
            "issn": "",
            "pages": "313--334",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Detection and management of antiviral resistance for infl uenza viruses",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Boivin",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Infl uenza Other Respir Viruses",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant infl uenza virus strains in vitro",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "T"
                    ],
                    "last": "Nguyen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Hoopes",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Le",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "PLoS One",
            "volume": "5",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "Combinations of oseltamivir and peramivir for the treatment of infl uenza A (H1N1) virus infections in cell culture and in mice",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Smee",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "L"
                    ],
                    "last": "Hurst",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Wong",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Antiviral Res",
            "volume": "88",
            "issn": "",
            "pages": "38--44",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "The structure of H5N1 avian infl uenza neuraminidase suggests new opportunities for drug design",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "J"
                    ],
                    "last": "Russell",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "F"
                    ],
                    "last": "Haire",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Stevens",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Nature",
            "volume": "443",
            "issn": "",
            "pages": "45--49",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Crystal structures of oseltamivirresistant infl uenza virus neuraminidase mutants",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "J"
                    ],
                    "last": "Collins",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "F"
                    ],
                    "last": "Haire",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "P"
                    ],
                    "last": "Lin",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Nature",
            "volume": "453",
            "issn": "",
            "pages": "1258--61",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Structural studies of the resistance of infl uenza virus neuramindase to inhibitors",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Smith",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Mckimm-Breshkin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Mcdonald",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "T"
                    ],
                    "last": "Fernley",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "N"
                    ],
                    "last": "Varghese",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "M"
                    ],
                    "last": "Colman",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "J Med Chem",
            "volume": "45",
            "issn": "",
            "pages": "2207--2219",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "In vitro selection and characterization of infl uenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Molla",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Kati",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Carrick",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "J Virol",
            "volume": "76",
            "issn": "",
            "pages": "5380--86",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human infl uenza virus H7N9 isolate can be masked by a mixed R/K viral population",
            "authors": [
                {
                    "first": "H",
                    "middle": [
                        "L"
                    ],
                    "last": "Yen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Mckimm-Breschkin",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "T"
                    ],
                    "last": "Choy",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "MBio",
            "volume": "4",
            "issn": "",
            "pages": "396--413",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Characterization of H7N9 infl uenza A viruses isolated from humans",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Watanabe",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Kiso",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Fukuyama",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Nature",
            "volume": "501",
            "issn": "",
            "pages": "551--55",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "Therapy of H7N9 pneumonia: current perspectives",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Expert Rev Anti Infect Ther",
            "volume": "11",
            "issn": "",
            "pages": "1123--1149",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Infl uenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Hai",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Schmolke",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "H"
                    ],
                    "last": "Leyva-Grado",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Nat Commun",
            "volume": "4",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "Eff ect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of infl uenza in households",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Carrat",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Duval",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Tubach",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Antivir Ther",
            "volume": "17",
            "issn": "",
            "pages": "1085--90",
            "other_ids": {}
        },
        "BIBREF47": {
            "ref_id": "b47",
            "title": "Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 infl uenza A(H1N1) virus infections",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Escuret",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Cornu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Boutitie",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Antiviral Res",
            "volume": "96",
            "issn": "",
            "pages": "130--167",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic infl uenza A (H1N1) infection",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "L"
                    ],
                    "last": "Fraaij",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Van Der Vries",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "F"
                    ],
                    "last": "Beersma",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Infect Dis",
            "volume": "204",
            "issn": "",
            "pages": "777--82",
            "other_ids": {}
        },
        "BIBREF49": {
            "ref_id": "b49",
            "title": "Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator-and ECMO-treated critically ill patients with pandemic infl uenza A (H1N1)v",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Petersen",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "B"
                    ],
                    "last": "Keld",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ellermann-Eriksen",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Scand J Infect Dis",
            "volume": "43",
            "issn": "",
            "pages": "495--503",
            "other_ids": {}
        },
        "BIBREF50": {
            "ref_id": "b50",
            "title": "Antiviral resistance among highly pathogenic infl uenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Govorkova",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Baranovich",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Seiler",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Antiviral Res",
            "volume": "98",
            "issn": "",
            "pages": "297--304",
            "other_ids": {}
        },
        "BIBREF51": {
            "ref_id": "b51",
            "title": "Enhancement of activity against infl uenza viruses by combinations of antiviral agents",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Douglas",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Simons",
                    "suffix": ""
                }
            ],
            "year": 1980,
            "venue": "Antimicrob Agents Chemother",
            "volume": "18",
            "issn": "",
            "pages": "536--577",
            "other_ids": {}
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "Anti-infl uenza A activity of combinations of amantadine and ribavirin in ferret tracheal ciliated epithelium",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "B"
                    ],
                    "last": "Burlington",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Meiklejohn",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Mostow",
                    "suffix": ""
                }
            ],
            "year": 1983,
            "venue": "J Antimicrob Chemother",
            "volume": "11",
            "issn": "",
            "pages": "7--14",
            "other_ids": {}
        },
        "BIBREF53": {
            "ref_id": "b53",
            "title": "Eff ects of double combinations of amantadine, oseltamivir, and ribavirin on infl uenza A (H5N1) virus infections in cell culture and in mice",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Smee",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "L"
                    ],
                    "last": "Hurst",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Wong",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "W"
                    ],
                    "last": "Bailey",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Morrey",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Antimicrob Agents Chemother",
            "volume": "53",
            "issn": "",
            "pages": "2120--2148",
            "other_ids": {}
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "Effi cacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant infl uenza A viruses",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "T"
                    ],
                    "last": "Nguyen",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Smee",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "L"
                    ],
                    "last": "Barnard",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "PLoS One",
            "volume": "7",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Morrison",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Roy",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Rayner",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "PLoS One",
            "volume": "2",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF56": {
            "ref_id": "b56",
            "title": "Combination treatment of infl uenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Smee",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "W"
                    ],
                    "last": "Bailey",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Morrison",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "W"
                    ],
                    "last": "Sidwell",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Chemotherapy",
            "volume": "48",
            "issn": "",
            "pages": "88--93",
            "other_ids": {}
        },
        "BIBREF57": {
            "ref_id": "b57",
            "title": "Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of infl uenza A (H1N1) and B viruses",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Smee",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Wong",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "W"
                    ],
                    "last": "Bailey",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "W"
                    ],
                    "last": "Sidwell",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Antivir Chem Chemother",
            "volume": "17",
            "issn": "",
            "pages": "185--92",
            "other_ids": {}
        },
        "BIBREF58": {
            "ref_id": "b58",
            "title": "Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 infl uenza virus infection in mice",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "A"
                    ],
                    "last": "Ilyushina",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Hay",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Yilmaz",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Boon",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Webster",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Govorkova",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Antimicrob Agents Chemother",
            "volume": "52",
            "issn": "",
            "pages": "3889--97",
            "other_ids": {}
        },
        "BIBREF59": {
            "ref_id": "b59",
            "title": "Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of infl uenza A (H1N1) and B viruses",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Smee",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Wong",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "W"
                    ],
                    "last": "Bailey",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "W"
                    ],
                    "last": "Sidwell",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Antivir Chem Chemother",
            "volume": "17",
            "issn": "",
            "pages": "185--92",
            "other_ids": {}
        },
        "BIBREF60": {
            "ref_id": "b60",
            "title": "Lack of eff ect of oral ribavirin in naturally occurring infl uenza A virus (H1N1) infection",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "B"
                    ],
                    "last": "Smith",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "P"
                    ],
                    "last": "Charette",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Fox",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "K"
                    ],
                    "last": "Cooney",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "E"
                    ],
                    "last": "Hall",
                    "suffix": ""
                }
            ],
            "year": 1980,
            "venue": "J Infect Dis",
            "volume": "141",
            "issn": "",
            "pages": "548--54",
            "other_ids": {}
        },
        "BIBREF61": {
            "ref_id": "b61",
            "title": "Oral ribavirin treatment of infl uenza A and B",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Stein",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Creticos",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "G"
                    ],
                    "last": "Jackson",
                    "suffix": ""
                }
            ],
            "year": 1987,
            "venue": "Antimicrob Agents Chemother",
            "volume": "31",
            "issn": "",
            "pages": "1285--87",
            "other_ids": {}
        },
        "BIBREF62": {
            "ref_id": "b62",
            "title": "The use of intravenous ribavirin to treat infl uenza virus-associated acute myocarditis",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "G"
                    ],
                    "last": "Ray",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "B"
                    ],
                    "last": "Icenogle",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "L"
                    ],
                    "last": "Minnich",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "G"
                    ],
                    "last": "Copeland",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "M"
                    ],
                    "last": "Grogan",
                    "suffix": ""
                }
            ],
            "year": 1989,
            "venue": "J Infect Dis",
            "volume": "159",
            "issn": "",
            "pages": "829--865",
            "other_ids": {}
        },
        "BIBREF63": {
            "ref_id": "b63",
            "title": "Intravenous ribavirin by constant infusion for serious infl uenza and parainfl uenzavirus infection",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "A"
                    ],
                    "last": "Sable",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Connor",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Lane",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Antivir Ther",
            "volume": "1",
            "issn": "",
            "pages": "51--56",
            "other_ids": {}
        },
        "BIBREF64": {
            "ref_id": "b64",
            "title": "Favorable outcome after treatment with amantadine and ribavirin in a pregnancy complicated by infl uenza pneumonia. A case report",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Kirshon",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Faro",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "K"
                    ],
                    "last": "Zurawin",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "C"
                    ],
                    "last": "Samo",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "J"
                    ],
                    "last": "Carpenter",
                    "suffix": ""
                }
            ],
            "year": 1988,
            "venue": "J Reprod Med",
            "volume": "33",
            "issn": "",
            "pages": "399--401",
            "other_ids": {}
        },
        "BIBREF65": {
            "ref_id": "b65",
            "title": "Use of ribavirin to treat infl uenza",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "M"
                    ],
                    "last": "Chan-Tack",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Murray",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "B"
                    ],
                    "last": "Birnkrant",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "N Engl J Med",
            "volume": "361",
            "issn": "",
            "pages": "1713--1727",
            "other_ids": {}
        },
        "BIBREF66": {
            "ref_id": "b66",
            "title": "Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple infl uenza virus strains in vitro",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "T"
                    ],
                    "last": "Nguyen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Hoopes",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Smee",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Antimicrob Agents Chemother",
            "volume": "53",
            "issn": "",
            "pages": "4115--4141",
            "other_ids": {}
        },
        "BIBREF67": {
            "ref_id": "b67",
            "title": "Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant infl uenza A virus",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Hoopes",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Driebe",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Kelley",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "PLoS One",
            "volume": "6",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF68": {
            "ref_id": "b68",
            "title": "Combination therapy with amantadine, oseltamivir and ribavirin for infl uenza A infection: safety and pharmacokinetics",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Seo",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Englund",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "T"
                    ],
                    "last": "Nguyen",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Antivir Ther",
            "volume": "18",
            "issn": "",
            "pages": "377--86",
            "other_ids": {}
        },
        "BIBREF69": {
            "ref_id": "b69",
            "title": "Triple-combination antiviral drug for pandemic H1N1 infl uenza virus infection in critically ill patients on mechanical ventilation",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "Y"
                    ],
                    "last": "Kim",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "G"
                    ],
                    "last": "Young",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "W"
                    ],
                    "last": "Huh",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Antimicrob Agents Chemother",
            "volume": "55",
            "issn": "",
            "pages": "5703--5712",
            "other_ids": {}
        },
        "BIBREF70": {
            "ref_id": "b70",
            "title": "Favipiravir (T-705), a novel viral RNA polymerase inhibitor",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Furuta",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "B"
                    ],
                    "last": "Gowen",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Takahashi",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Shiraki",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Smee",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "L"
                    ],
                    "last": "Barnard",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Antiviral Res",
            "volume": "100",
            "issn": "",
            "pages": "446--54",
            "other_ids": {}
        },
        "BIBREF71": {
            "ref_id": "b71",
            "title": "Eff ects of the combination of favipiravir (T-705) and oseltamivir on infl uenza A virus infections in mice",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Smee",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "L"
                    ],
                    "last": "Hurst",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Wong",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Antimicrob Agents Chemother",
            "volume": "54",
            "issn": "",
            "pages": "126--159",
            "other_ids": {}
        },
        "BIBREF72": {
            "ref_id": "b72",
            "title": "Combinations of favipiravir and peramivir for the treatment of pandemic infl uenza A/California/04/2009 (H1N1) virus infections in mice",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "B"
                    ],
                    "last": "Tarbet",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Maekawa",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Furuta",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "S"
                    ],
                    "last": "Babu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Morrey",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Smee",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Antiviral Res",
            "volume": "94",
            "issn": "",
            "pages": "103--113",
            "other_ids": {}
        },
        "BIBREF73": {
            "ref_id": "b73",
            "title": "The new drug application approval of \"AVIGAN\u00ae tablet 200mg\" in Japan for the anti-infl uenza virus drug",
            "authors": [
                {
                    "first": "Toyama Chemical",
                    "middle": [],
                    "last": "Co",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "June",
            "volume": "23",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF74": {
            "ref_id": "b74",
            "title": "Clinical eff ectiveness and safety of favipiravir, a novel anti-infl uenza drug with a selective inhibition activity against viral RNA polymerase",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Kobayashi",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Kashiwagi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Iwamoto",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF75": {
            "ref_id": "b75",
            "title": "A phase 2, randomized, double blind, placebocontrolled, multicenter study evaluating the safety and pharmacokinetics of diff erent dosing regimens of favipiravir (T-705) in adult subjects with uncomplicated infl uenza. Abstact O-905. Options for Control of Infl uenza VII",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Epstein",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF76": {
            "ref_id": "b76",
            "title": "Treatment with convalescent plasma for infl uenza A (H5N1) infection",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "N Engl J Med",
            "volume": "357",
            "issn": "",
            "pages": "1450--51",
            "other_ids": {}
        },
        "BIBREF77": {
            "ref_id": "b77",
            "title": "Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 infl uenza A(H1N1) infection",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "F"
                    ],
                    "last": "Hung",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "K"
                    ],
                    "last": "To",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "K"
                    ],
                    "last": "Lee",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Chest",
            "volume": "144",
            "issn": "",
            "pages": "464--73",
            "other_ids": {}
        },
        "BIBREF78": {
            "ref_id": "b78",
            "title": "Broadly neutralizing antibodies against infl uenza virus and prospects for universal therapies",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "C"
                    ],
                    "last": "Ekiert",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "A"
                    ],
                    "last": "Wilson",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Curr Opin Virol",
            "volume": "2",
            "issn": "",
            "pages": "134--175",
            "other_ids": {}
        },
        "BIBREF79": {
            "ref_id": "b79",
            "title": "A highly conserved neutralizing epitope on group 2 infl uenza A viruses",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "C"
                    ],
                    "last": "Ekiert",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "H"
                    ],
                    "last": "Friesen",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Bhabha",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Science",
            "volume": "333",
            "issn": "",
            "pages": "843--50",
            "other_ids": {}
        },
        "BIBREF80": {
            "ref_id": "b80",
            "title": "A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 infl uenza A hemagglutinins",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Corti",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Voss",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "J"
                    ],
                    "last": "Gamblin",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Science",
            "volume": "333",
            "issn": "",
            "pages": "850--56",
            "other_ids": {}
        },
        "BIBREF81": {
            "ref_id": "b81",
            "title": "An in vivo humanplasmablast enrichment technique allows rapid identifi cation of therapeutic infl uenza a antibodies",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Nakamura",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Chai",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Park",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Cell Host Microbe",
            "volume": "14",
            "issn": "",
            "pages": "93--103",
            "other_ids": {}
        },
        "BIBREF82": {
            "ref_id": "b82",
            "title": "Antivirals in seasonal and pandemic infl uenza-future perspectives",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "W"
                    ],
                    "last": "Wathen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Barro",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Bright",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Infl uenza Other Respir Viruses",
            "volume": "",
            "issn": "7",
            "pages": "76--80",
            "other_ids": {}
        },
        "BIBREF83": {
            "ref_id": "b83",
            "title": "In vitro susceptibility of canine infl uenza A (H3N8) virus to nitazoxanide and tizoxanide",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "V"
                    ],
                    "last": "Ashton",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "L"
                    ],
                    "last": "Callan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Rao",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Landolt",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Vet Med Int",
            "volume": "2010",
            "issn": "",
            "pages": "1--5",
            "other_ids": {}
        },
        "BIBREF84": {
            "ref_id": "b84",
            "title": "A novel potential anti-infl uenza drug, acting in synergism with neuraminidase inhibitors",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Belardo",
                    "suffix": ""
                },
                {
                    "first": "La",
                    "middle": [],
                    "last": "Frazia",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Cenciareli",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Carta",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Rossignol",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "F"
                    ],
                    "last": "Santoro",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "49th Infectious Disease Society of America Annual Meeting: New Approaches to Anti-Viral Therapy",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF86": {
            "ref_id": "b86",
            "title": "Thiazolides, a new class of anti-infl uenza molecules targeting viral hemagglutinin at the post-translational level",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "F"
                    ],
                    "last": "Rossignol",
                    "suffix": ""
                },
                {
                    "first": "La",
                    "middle": [],
                    "last": "Frazia",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Chiappa",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Ciucci",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Santoro",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "J Biol Chem",
            "volume": "284",
            "issn": "",
            "pages": "29798--808",
            "other_ids": {}
        },
        "BIBREF88": {
            "ref_id": "b88",
            "title": "A randomized, double-blind, placebo (PCB) controlled clinical trial of nitazoxanide (NTZ) in adults and adolescents with acute uncomplicated infl uenza",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "F"
                    ],
                    "last": "Rossignol",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Samudrals",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hoppers",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Haffi",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "49th Infectious Disease Society of America Annual Meeting",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF89": {
            "ref_id": "b89",
            "title": "LB-35",
            "authors": [],
            "year": 2011,
            "venue": "DSA Annual Meeting",
            "volume": "23",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF90": {
            "ref_id": "b90",
            "title": "Sialidase fusion protein as a novel broad-spectrum inhibitor of infl uenza virus infection",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "P"
                    ],
                    "last": "Malakhov",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "M"
                    ],
                    "last": "Aschenbrenner",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Smee",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Antimicrob Agents Chemother",
            "volume": "50",
            "issn": "",
            "pages": "1470--79",
            "other_ids": {}
        },
        "BIBREF91": {
            "ref_id": "b91",
            "title": "DAS181, a novel sialidase fusion protein, protects mice from lethal avian infl uenza H5N1 virus infection",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Belser",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "J"
                    ],
                    "last": "Szretter",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "J Infect Dis",
            "volume": "196",
            "issn": "",
            "pages": "1493--99",
            "other_ids": {}
        },
        "BIBREF92": {
            "ref_id": "b92",
            "title": "Novel pandemic infl uenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "B"
                    ],
                    "last": "Triana-Baltzer",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "V"
                    ],
                    "last": "Gubareva",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Nicholls",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "PLoS One",
            "volume": "4",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF93": {
            "ref_id": "b93",
            "title": "Phenotypic and genotypic characterization of infl uenza virus mutants selected with the sialidase fusion protein DAS181",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "B"
                    ],
                    "last": "Triana-Baltzer",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "L"
                    ],
                    "last": "Sanders",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hedlund",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Antimicrob Chemother",
            "volume": "66",
            "issn": "",
            "pages": "15--28",
            "other_ids": {}
        },
        "BIBREF94": {
            "ref_id": "b94",
            "title": "A phase II study of DAS181, a novel host directed antiviral for the treatment of infl uenza infection",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "B"
                    ],
                    "last": "Moss",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Hansen",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "L"
                    ],
                    "last": "Sanders",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Hawley",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "T"
                    ],
                    "last": "Steigbigel",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Infect Dis",
            "volume": "206",
            "issn": "",
            "pages": "1844--51",
            "other_ids": {}
        },
        "BIBREF95": {
            "ref_id": "b95",
            "title": "Treatment of parainfl uenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation",
            "authors": [
                {
                    "first": "Y",
                    "middle": [
                        "B"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Driscoll",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "L"
                    ],
                    "last": "Mcafee",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Clin Infect Dis",
            "volume": "53",
            "issn": "",
            "pages": "77--80",
            "other_ids": {}
        },
        "BIBREF96": {
            "ref_id": "b96",
            "title": "DAS181 treatment of severe parainfl uenza type 3 pneumonia in a lung transplant recipient",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "R"
                    ],
                    "last": "Drozd",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "P"
                    ],
                    "last": "Limaye",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "B"
                    ],
                    "last": "Moss",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Transpl Infect Dis",
            "volume": "15",
            "issn": "",
            "pages": "28--32",
            "other_ids": {}
        },
        "BIBREF97": {
            "ref_id": "b97",
            "title": "Arbidol: a broad-spectrum antiviral compound that blocks viral fusion",
            "authors": [
                {
                    "first": "Y",
                    "middle": [
                        "S"
                    ],
                    "last": "Boriskin",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "A"
                    ],
                    "last": "Leneva",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "I"
                    ],
                    "last": "Pecheur",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "J"
                    ],
                    "last": "Polyak",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Curr Med Chem",
            "volume": "15",
            "issn": "",
            "pages": "997--1005",
            "other_ids": {}
        },
        "BIBREF98": {
            "ref_id": "b98",
            "title": "Characteristics of arbidol-resistant mutants of infl uenza virus: implications for the mechanism of anti-infl uenza action of arbidol",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "A"
                    ],
                    "last": "Leneva",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "J"
                    ],
                    "last": "Russell",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "S"
                    ],
                    "last": "Boriskin",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Hay",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Antiviral Res",
            "volume": "81",
            "issn": "",
            "pages": "132--172",
            "other_ids": {}
        },
        "BIBREF99": {
            "ref_id": "b99",
            "title": "Antiviral activity of arbidol against infl uenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Xiong",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Arch Virol",
            "volume": "152",
            "issn": "",
            "pages": "1447--55",
            "other_ids": {}
        },
        "BIBREF100": {
            "ref_id": "b100",
            "title": "Infl uence of arbidol combination with diff erent antiviral drugs on reproduction of infl uenza virus A",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "A"
                    ],
                    "last": "Leneva",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "T"
                    ],
                    "last": "Fediakina",
                    "suffix": ""
                },
                {
                    "first": "Gus",
                    "middle": [
                        "&apos;"
                    ],
                    "last": "Ta",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Glushkov",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Ter Arkh",
            "volume": "77",
            "issn": "",
            "pages": "84--88",
            "other_ids": {}
        },
        "BIBREF101": {
            "ref_id": "b101",
            "title": "VX-787 showed signifi cant antiviral activity and reduced the severity and duration of infl uenza symptoms in phase 2 challenge study",
            "authors": [],
            "year": 2014,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF102": {
            "ref_id": "b102",
            "title": "AVI-7100 is eff ective in oseltamivir resistant H1N1 infected ferrets. Abstract F1-13725a. Presented at the 51st Interscience conference on Antimicrobial Agents and Chemoterapy (ICAAC)",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "L"
                    ],
                    "last": "Iversen",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "V"
                    ],
                    "last": "Mourich",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Voss",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF103": {
            "ref_id": "b103",
            "title": "AVI-7100 prevents transmission from oseltamivir resistant H1N1 viral infected to na\u00efve ferrets. Presented at the 51st Interscience conference on Antimicrobial Agents and Chemotherapy (ICAAC)",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "L"
                    ],
                    "last": "Iverson",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "V"
                    ],
                    "last": "Mourich",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Voss",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "A"
                    ],
                    "last": "Bothwell",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF104": {
            "ref_id": "b104",
            "title": "Adjunctive therapies and immunomodulatory agents in the management of severe infl uenza",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Hui",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "K"
                    ],
                    "last": "Chan",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Antiviral Res",
            "volume": "98",
            "issn": "",
            "pages": "410--426",
            "other_ids": {}
        },
        "BIBREF105": {
            "ref_id": "b105",
            "title": "Treating infl uenza with statins and other immunomodulatory agents",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Fedson",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Antiviral Res",
            "volume": "99",
            "issn": "",
            "pages": "417--452",
            "other_ids": {}
        },
        "BIBREF106": {
            "ref_id": "b106",
            "title": "Innate immune induction and infl uenza protection elicited by a response-selective agonist of human C5a",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "D"
                    ],
                    "last": "Sanderson",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Thoman",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Kis",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "PLoS One",
            "volume": "7",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF107": {
            "ref_id": "b107",
            "title": "Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Goulet",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Olagnier",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "PLoS Pathog",
            "volume": "9",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF108": {
            "ref_id": "b108",
            "title": "The TLR4 antagonist Eritoran protects mice from lethal infl uenza infection",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Shirey",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Lai",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Scott",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Nature",
            "volume": "497",
            "issn": "",
            "pages": "498--502",
            "other_ids": {}
        },
        "BIBREF109": {
            "ref_id": "b109",
            "title": "The lipid mediator protectin D1 inhibits infl uenza virus replication and improves severe infl uenza",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Morita",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Kuba",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Ichikawa",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Cell",
            "volume": "153",
            "issn": "",
            "pages": "112--137",
            "other_ids": {}
        },
        "BIBREF110": {
            "ref_id": "b110",
            "title": "Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of infl uenza A virus",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Lejal",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Tarus",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Bouguyon",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Antimicrob Agents Chemother",
            "volume": "57",
            "issn": "",
            "pages": "2231--2273",
            "other_ids": {}
        },
        "BIBREF111": {
            "ref_id": "b111",
            "title": "End points for testing infl uenza antiviral treatments for patients at high risk of severe and life-threatening disease",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Ison",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "De Jong",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "J"
                    ],
                    "last": "Gilligan",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "J Infect Dis",
            "volume": "201",
            "issn": "",
            "pages": "1654--62",
            "other_ids": {}
        },
        "BIBREF112": {
            "ref_id": "b112",
            "title": "Inhibition of infl uenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identifi ed by gene-trap insertional mutagenesis",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Murray",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "J"
                    ],
                    "last": "Mcdonald",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Sheng",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Antivir Chem Chemother",
            "volume": "22",
            "issn": "",
            "pages": "205--220",
            "other_ids": {}
        },
        "BIBREF113": {
            "ref_id": "b113",
            "title": "Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral eff ects after infl uenza A virus infection in vitro",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Haasbach",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Hartmayer",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Planz",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Antiviral Res",
            "volume": "98",
            "issn": "",
            "pages": "319--343",
            "other_ids": {}
        },
        "BIBREF114": {
            "ref_id": "b114",
            "title": "Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal infl uenza viral infection in a mouse model",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Ghezzi",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Ungheri",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Int J Immunopathol Pharmacol",
            "volume": "17",
            "issn": "",
            "pages": "99--102",
            "other_ids": {}
        },
        "BIBREF115": {
            "ref_id": "b115",
            "title": "N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal infl uenza infection",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Garozzo",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Tempera",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Ungheri",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Timpanaro",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Castro",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Int J Immunopathol Pharmacol",
            "volume": "20",
            "issn": "",
            "pages": "349--54",
            "other_ids": {}
        },
        "BIBREF116": {
            "ref_id": "b116",
            "title": "Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic infl uenza virus",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "B"
                    ],
                    "last": "Walsh",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Teijaro",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "R"
                    ],
                    "last": "Wilker",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Proc Natl Acad Sci",
            "volume": "108",
            "issn": "",
            "pages": "12018--12041",
            "other_ids": {}
        },
        "BIBREF117": {
            "ref_id": "b117",
            "title": "Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of infl uenza A/H5N1 virus",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "W"
                    ],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "P"
                    ],
                    "last": "Lin",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Proc Natl Acad Sci",
            "volume": "105",
            "issn": "",
            "pages": "8091--96",
            "other_ids": {}
        },
        "BIBREF118": {
            "ref_id": "b118",
            "title": "Effi cacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with infl uenza A virus",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "D&apos;agostini",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "T"
                    ],
                    "last": "Palamara",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Favalli",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Int J Immunopharmacol",
            "volume": "18",
            "issn": "",
            "pages": "95--102",
            "other_ids": {}
        },
        "BIBREF119": {
            "ref_id": "b119",
            "title": "Laninamivir octanoate and artifi cial surfactant combination therapy signifi cantly increases survival of mice infected with lethal infl uenza H1N1 virus",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Fukushi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Yamashita",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Miyoshi-Akiyama",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Kubo",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Yamamoto",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Kudo",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "PLoS One",
            "volume": "7",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF120": {
            "ref_id": "b120",
            "title": "Targeting organic anion transporter 3 with probenecid as a novel anti-infl uenza a virus strategy",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Perwitasari",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Johnson",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Antimicrob Agents Chemother",
            "volume": "57",
            "issn": "",
            "pages": "475--83",
            "other_ids": {}
        },
        "BIBREF121": {
            "ref_id": "b121",
            "title": "Pharmacokinetics of high-dose oseltamivir in healthy volunteers",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wattanagoon",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Stepniewska",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Lindegardh",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Antimicrob Agents Chemother",
            "volume": "53",
            "issn": "",
            "pages": "945--52",
            "other_ids": {}
        },
        "BIBREF122": {
            "ref_id": "b122",
            "title": "Simvastatin and oseltamivir combination therapy does not improve the eff ectiveness of oseltamivir alone following highly pathogenic avian H5N1 infl uenza virus infection in mice",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Belser",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "J"
                    ],
                    "last": "Szretter",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Katz",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "M"
                    ],
                    "last": "Tumpey",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Virology",
            "volume": "439",
            "issn": "",
            "pages": "42--46",
            "other_ids": {}
        },
        "BIBREF123": {
            "ref_id": "b123",
            "title": "Triple combinations of neuraminidase inhibitors, statins and fi brates benefi t the survival of patients with lethal avian infl uenza pandemic",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "C"
                    ],
                    "last": "An",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "L"
                    ],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "D"
                    ],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "L"
                    ],
                    "last": "Bao",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Qin",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [
                        "C"
                    ],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Med Hypotheses",
            "volume": "77",
            "issn": "",
            "pages": "1054--57",
            "other_ids": {}
        },
        "BIBREF124": {
            "ref_id": "b124",
            "title": "Eff ect of immunomodulatory therapies in patients with pandemic infl uenza A (H1N1) 2009 complicated by pneumonia",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Viasus",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Pano-Pardo",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Cordero",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Infect",
            "volume": "62",
            "issn": "",
            "pages": "193--99",
            "other_ids": {}
        },
        "BIBREF125": {
            "ref_id": "b125",
            "title": "Clarithromycin has limited eff ects in non-elderly, non-severe patients with seasonal infl uenza virus A infection",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Ishii",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Komiya",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Yamagata",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Infect",
            "volume": "64",
            "issn": "",
            "pages": "343--388",
            "other_ids": {}
        },
        "BIBREF126": {
            "ref_id": "b126",
            "title": "Macrolidebased regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Martin-Loeches",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "F"
                    ],
                    "last": "Bermejo-Martin",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Valles",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Intensive Care Med",
            "volume": "39",
            "issn": "",
            "pages": "693--702",
            "other_ids": {}
        },
        "BIBREF127": {
            "ref_id": "b127",
            "title": "Association between use of statins and mortality among patients hospitalized with laboratory-confi rmed infl uenza virus infections: a multistate study",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Vandermeer",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "R"
                    ],
                    "last": "Thomas",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Kamimoto",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Infect Dis",
            "volume": "205",
            "issn": "",
            "pages": "13--19",
            "other_ids": {}
        },
        "BIBREF128": {
            "ref_id": "b128",
            "title": "Population-based study of statins, angiotensin II receptor blockers, and angiotensinconverting enzyme inhibitors on pneumonia-related outcomes",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Mortensen",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Nakashima",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Cornell",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Clin Infect Dis",
            "volume": "55",
            "issn": "",
            "pages": "1466--73",
            "other_ids": {}
        },
        "BIBREF129": {
            "ref_id": "b129",
            "title": "Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Chopra",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Rogers",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Buist",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Am J Med",
            "volume": "125",
            "issn": "",
            "pages": "1111--1134",
            "other_ids": {}
        },
        "BIBREF130": {
            "ref_id": "b130",
            "title": "Eff ect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Makris",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Manoulakas",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Komnos",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Crit Care Med",
            "volume": "39",
            "issn": "",
            "pages": "2440--2486",
            "other_ids": {}
        },
        "BIBREF131": {
            "ref_id": "b131",
            "title": "Absence of interferon in lungs fom fatal cases of infl uenza",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Baron",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Isaacs",
                    "suffix": ""
                }
            ],
            "year": 1962,
            "venue": "BMJ",
            "volume": "1",
            "issn": "",
            "pages": "18--20",
            "other_ids": {}
        },
        "BIBREF132": {
            "ref_id": "b132",
            "title": "Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Agrati",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Gioia",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Lalle",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "J Infect Dis",
            "volume": "202",
            "issn": "",
            "pages": "681--89",
            "other_ids": {}
        },
        "BIBREF133": {
            "ref_id": "b133",
            "title": "Early control of H5N1 infl uenza virus replication by the type I interferon response in mice",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "J"
                    ],
                    "last": "Szretter",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Gangappa",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Belser",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "J Virol",
            "volume": "83",
            "issn": "",
            "pages": "5825--5859",
            "other_ids": {}
        },
        "BIBREF134": {
            "ref_id": "b134",
            "title": "Exogenous IFN-alpha administration reduces infl uenza A virus replication in the lower respiratory tract of rhesus macaques",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Matzinger",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "D"
                    ],
                    "last": "Carroll",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Fritts",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "B"
                    ],
                    "last": "Mcchesney",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Miller",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "PLoS One",
            "volume": "6",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF135": {
            "ref_id": "b135",
            "title": "Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Loutfy",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "M"
                    ],
                    "last": "Blatt",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Siminovitch",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "JAMA",
            "volume": "290",
            "issn": "",
            "pages": "3222--3250",
            "other_ids": {}
        },
        "BIBREF136": {
            "ref_id": "b136",
            "title": "Hyperinduction of cyclooxygenase-2-mediated proinfl ammatory cascade: a mechanism for the pathogenesis of avian infl uenza H5N1 infection",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "Y"
                    ],
                    "last": "Cheung",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Nicholls",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J Infect Dis",
            "volume": "198",
            "issn": "",
            "pages": "525--560",
            "other_ids": {}
        },
        "BIBREF137": {
            "ref_id": "b137",
            "title": "Early corticosteroids in severe infl uenza A/H1N1 pneumonia and acute respiratory distress syndrome",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Brun-Buisson",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Richard",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mercat",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Thiebaut",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Brochard",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Am J Respir Crit Care Med",
            "volume": "183",
            "issn": "",
            "pages": "1200--1206",
            "other_ids": {}
        },
        "BIBREF138": {
            "ref_id": "b138",
            "title": "Use of early corticosteroid therapy on ICU admission in patients aff ected by severe pandemic (H1N1)v infl uenza A infection",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Martin-Loeches",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Lisboa",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Rhodes",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Intensive Care Med",
            "volume": "37",
            "issn": "",
            "pages": "272--83",
            "other_ids": {}
        },
        "BIBREF139": {
            "ref_id": "b139",
            "title": "Hospitalized adult patients with 2009 infl uenza A(H1N1) in Beijing, China: risk factors for hospital mortality",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Xi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Duan",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "BMC Infect Dis",
            "volume": "10",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF140": {
            "ref_id": "b140",
            "title": "Corticosteroid treatment in critically ill patients with pandemic infl uenza A/H1N1 2009 infection: analytic strategy using propensity scores",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "H"
                    ],
                    "last": "Kim",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "B"
                    ],
                    "last": "Hong",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "C"
                    ],
                    "last": "Yun",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Am J Respir Crit Care Med",
            "volume": "183",
            "issn": "",
            "pages": "1207--1221",
            "other_ids": {}
        },
        "BIBREF141": {
            "ref_id": "b141",
            "title": "Chinese medicinal materials and their interface with western medical concepts",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Chan",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Ethnopharmacol",
            "volume": "96",
            "issn": "",
            "pages": "1--18",
            "other_ids": {}
        },
        "BIBREF142": {
            "ref_id": "b142",
            "title": "Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 infl uenza: a randomized trial",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [
                        "Q"
                    ],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Ann Intern Med",
            "volume": "155",
            "issn": "",
            "pages": "217--242",
            "other_ids": {}
        },
        "BIBREF143": {
            "ref_id": "b143",
            "title": "Experimental human infl uenza: observations from studies of infl uenza antivirals",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Antivir Ther",
            "volume": "17",
            "issn": "",
            "pages": "133--174",
            "other_ids": {}
        },
        "BIBREF144": {
            "ref_id": "b144",
            "title": "Adaptive trial designs: a review of barriers and opportunities",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Kairalla",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "S"
                    ],
                    "last": "Coff Ey",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Thomann",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "E"
                    ],
                    "last": "Muller",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Trials",
            "volume": "13",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "These fi ndings are consistent with",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Representative antiviral combinations that have been studied or are presently in trials, by study type",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Both individual agents accelerated fever resolution compared with placebo, and the combination showed a borderline statistically signifi cant reduction in time to fever resolution compared with oseltamivir alone (median hours to alleviation of fever, 20\u00b70 [95% CI 17\u00b70 to 24\u00b70] vs 15\u00b70 [12\u00b70 to 18\u00b70]). However, no diff erence in the reduction of symptom scores and duration of viral shedding between combination therapy and oseltamivir monotherapy were found. Other clinical studies Specifi c considerations Availability of drug Regulatory approval status, generic availability, cost, importation restrictions Route of administration Inhaled/topical Delivery device features; nebulisation potential in infants Eff ective delivery in severe and pneumonic disease; bronchospasm risk Injected Reliable delivery in seriously ill patients, need for injection equipment and higher resourced setting Complexity of dosing regimen Compatibility of co-formulation (eg, potential single-dose form) Applicability across age spectrum (infants, elderly people) Applicability in low resource setting Compliance Adverse event profi le Risk-benefi t profi le in outpatients and specifi c target populations Safety in infants and pregnancy Antiviral potency and spectrum Results from preclinical models Ability to rapidly control replication Antiviral resistance emergence Frequency, rapidity, cross-resistance patterns, viral fi tness consequences Immunomodulatory eff ects Timing of initiation and cessation of intervention Target population based on disease pathogenesis Cost Eff ect on breadth of use Cost-benefi t in outpatients Availability in low-resource settings",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "Considerations in selecting antiviral combinations for study",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}